Increased Cardiovascular Implantable Electronic Device Infections

By Staff Writer

October 31, 2023

Understanding the Growing Concern

Cardiovascular Implantable Electronic Devices (CIEDs) are life-saving marvels of modern medicine. However, with over 300,000 patients receiving a new CIED implantation annually in the US alone, there has been a simultaneous surge in device infections. These infections can lead to substantial morbidity, with infected patients facing over 3-fold higher mortality compared to those without infections. Moreover, the financial burden on the healthcare system is significant.

The Significance of Prompt Intervention

The efficacy of antibiotics as a standalone treatment for CIED infection is limited. These factors have the potential to result in increased rates of infection relapse and fatality. In patients diagnosed with a definite CIED infection, the recommended course of action is the comprehensive extraction of both the device and lead. Research findings indicate that conducting extractions promptly following diagnosis leads to notable reductions in 1-year mortality rates, shorter durations of hospitalisation, and a decreased frequency of physician or hospital visits.

CIED infections and early intervention

There are concerns about the lack of compliance with guidelines for removing hardware from patients with CIED infections. The goal of this analysis was to measure the number of Medicare beneficiaries with CIED-related infections. These patients had lead extraction procedures between 2007 and 2019.  Additionally, the study attempted to analyse the resulting outcomes of these interventions. The researchers discovered that the process of lead extraction was linked to a decrease in mortality rates. Furthermore, they observed that conducting lead extraction at an earlier stage was correlated with even lower mortality rates compared to delaying the procedure.

This study identifies the need for comprehensive care in managing CIED infection. This includes identifying the infection, conducting a thorough examination, starting antibiotic treatment, making appropriate referrals, and deciding if extraction is needed. The study’s results highlight the urgent need to follow care guidelines more closely. They also stress the importance of improving quality within health systems. 

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.